Dispatch · June 27, 2026 · 8 min read

GLP-1 and Male Fertility: ENDO 2026 Confirms What Men Hoped Was True

For men taking GLP-1 medications who are planning to start a family — or want to keep that option open — the most important research of 2026 arrived at the Endocrine Society's annual meeting in Chicago. The message is clear and encouraging: GLP-1 medications do not harm male fertility. In fact, they may improve it.

The Fertility Fear

The concern was reasonable. Testosterone replacement therapy — the most common treatment for obesity-related low testosterone — causes a well-documented and often severe decline in sperm production. Some men on TRT experience complete azoospermia (zero sperm count), and recovery isn't always guaranteed. When GLP-1 medications entered the conversation as another tool for the obesity-hormone connection, men understandably worried about similar reproductive consequences.

The ENDO 2026 data puts those fears to rest.

What the Warwick Medical School Found

A systematic review of five randomized controlled trials examined GLP-1 medications across multiple compounds — semaglutide, liraglutide, and dulaglutide — and measured their effects on male reproductive hormones, sperm quality, and sexual function.

The headline findings:

GLP-1 vs. TRT for Fertility-Minded Men

This is where the data gets particularly significant. A 16-week study compared liraglutide to testosterone replacement therapy in men with obesity and low testosterone. Both groups saw testosterone levels rise. But the liraglutide group achieved this without suppressing the HPG axis — the hormonal feedback loop that controls sperm production — while TRT, by definition, shuts that axis down.

For men who want to improve their testosterone and preserve fertility simultaneously, GLP-1 therapy addresses the underlying cause (excess fat suppressing hormone production) rather than replacing the hormone externally. This is a fundamentally different — and for fertility purposes, superior — approach.

The Mechanism: Why GLP-1s Help

Obesity impairs male fertility through several well-understood pathways. Excess adipose tissue increases aromatase activity, converting testosterone to estrogen. Visceral fat drives chronic inflammation that damages testicular tissue. Insulin resistance disrupts the hormonal signals between the brain and testes.

GLP-1 medications address all of these simultaneously through weight loss and direct metabolic improvement. As visceral fat decreases, aromatase activity drops, testosterone rises, and the hormonal environment for sperm production improves. The research team at Warwick concluded that GLP-1s "do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss."

What Men Planning Families Should Do

If you're on or considering GLP-1 therapy and fertility matters to you — now or in the future — here's the practical guidance:

Get a baseline semen analysis before starting treatment. This gives you a reference point and may reveal pre-existing issues worth addressing.

Check testosterone, LH, and FSH at baseline and every 3-6 months during treatment. You should see these stabilize or improve.

If you're currently on TRT for obesity-related low T, discuss with your provider whether transitioning to GLP-1 therapy could restore natural testosterone production while preserving fertility. The ENDO 2026 data supports this approach.

Continue standard fertility-supportive habits: avoid excessive heat to the testes, limit alcohol, maintain healthy weight, exercise regularly, and manage stress. GLP-1 therapy enhances these efforts — it doesn't replace them.